Cardax Inc (CDXI) 0.4400 $CDXI
Cardax to Lead Aging Discussion at Chaminade University
Business Wire - Tue Oct 06, 7:00AM CDT
Cardax, Inc. ("Cardax"
(OTCQB:CDXI) announced today that it will be leading a discussion on aging at Chaminade University's Public Policy Forum series on October 28, 2015.
Cardax Product Candidates Demonstrate Superior Bioavailability vs. Microalgal Astaxanthin in Monkey Study
Business Wire - Wed Jul 29, 7:00AM CDT
Cardax, Inc. ("Cardax" (OTCQB:CDXI) announced today that its astaxanthin consumer health candidates CDX-085 and ASTX-1F demonstrated more than two and one-half times higher oral bioavailability than a leading microalgal astaxanthin product in a head-to-head monkey study. The study was conducted by top-tier contract research organizations and bioavailability was determined by measuring the plasma exposure of astaxanthin over four days following a single dose.
Cardax Raises Additional $500,000 in Financing
Business Wire - Tue Jun 30, 7:00AM CDT
Cardax, Inc. ("Cardax" (OTCQB:CDXI) announced today that it has closed on an additional $500,000 in equity financing, bringing the year-to-date amount raised in its issuer-directed unit offering to $1,125,000.
Cardax Initiates Monkey Study to Compare Bioavailability of Patented Consumer Health Product Candidate CDX-085 to Microalgal Astaxanthin
Business Wire - Thu Jun 18, 7:00AM CDT
Cardax, Inc. ("Cardax" (OTCQB:CDXI) announced today that it initiated a single-dose pharmacokinetic study in non-human primates (monkeys) to compare the bioavailability (exposure) of CDX-085, the Company's patented consumer health product candidate, to microalgal astaxanthin, the predominate astaxanthin consumer health form on the market.
SeeThruEquity Initiates Research Coverage on Cardax, Inc. with a Target Price of $1.00
ACCESSWIRE - Mon Oct 06, 8:06AM CDT
New York, NY / ACCESSWIRE / October 6, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Cardax, Inc. (OTCQB: CDXI), Cardax is a development stage, life sciences company focused on introducing nutraceutical and pharmaceutical products aimed at reducing inflammation and oxidative stress.
Cardax to Lead Aging Discussion at Chaminade University
Business Wire - Tue Oct 06, 7:00AM CDT
Cardax, Inc. ("Cardax"
(OTCQB:CDXI) announced today that it will be leading a discussion on aging at Chaminade University's Public Policy Forum series on October 28, 2015. Cardax Product Candidates Demonstrate Superior Bioavailability vs. Microalgal Astaxanthin in Monkey Study
Business Wire - Wed Jul 29, 7:00AM CDT
Cardax, Inc. ("Cardax"
(OTCQB:CDXI) announced today that its astaxanthin consumer health candidates CDX-085 and ASTX-1F demonstrated more than two and one-half times higher oral bioavailability than a leading microalgal astaxanthin product in a head-to-head monkey study. The study was conducted by top-tier contract research organizations and bioavailability was determined by measuring the plasma exposure of astaxanthin over four days following a single dose. Cardax Raises Additional $500,000 in Financing
Business Wire - Tue Jun 30, 7:00AM CDT
Cardax, Inc. ("Cardax"
(OTCQB:CDXI) announced today that it has closed on an additional $500,000 in equity financing, bringing the year-to-date amount raised in its issuer-directed unit offering to $1,125,000. Cardax Initiates Monkey Study to Compare Bioavailability of Patented Consumer Health Product Candidate CDX-085 to Microalgal Astaxanthin
Business Wire - Thu Jun 18, 7:00AM CDT
Cardax, Inc. ("Cardax"
(OTCQB:CDXI) announced today that it initiated a single-dose pharmacokinetic study in non-human primates (monkeys) to compare the bioavailability (exposure) of CDX-085, the Company's patented consumer health product candidate, to microalgal astaxanthin, the predominate astaxanthin consumer health form on the market. SeeThruEquity Initiates Research Coverage on Cardax, Inc. with a Target Price of $1.00
ACCESSWIRE - Mon Oct 06, 8:06AM CDT
New York, NY / ACCESSWIRE / October 6, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Cardax, Inc. (OTCQB: CDXI), Cardax is a development stage, life sciences company focused on introducing nutraceutical and pharmaceutical products aimed at reducing inflammation and oxidative stress.
